Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency
Author:
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 123, S58-S61
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 TrialJACC, 2007
- Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practiceJournal of Thrombosis and Haemostasis, 2007
- Elderly Medical Patients Treated with Prophylactic Dosages of EnoxaparinDrugs & Aging, 2007
- Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal InsufficiencyAnnals of Internal Medicine, 2006
- The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patientsJournal of Thrombosis and Haemostasis, 2004
- Heparin and Low-Molecular-Weight HeparinChest, 2004
- Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With EnoxaparinCirculation, 2004
- Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studiesAmerican Heart Journal, 2003
- A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric SurgeryObesity Surgery, 2002
- Safety Profile of Tinzaparin Administered Once Daily at a Standard Curative Dose in Two Hundred Very Elderly PatientsDrug Safety, 2002